A Peek Into The Market Before The Trading Starts
Pre-open movers US stock futures are higher this morning, as investors are awaiting jobless claims and consumer confidence data. Futures for the Dow Jones Industrial Average gained 11 points to 13,059.00 and S&P 500 index futures rose 1.50 points to 1,415.00. Nasdaq 100 futures climbed 5.50 points to 2,634.00.
A Peek Into Global Markets European markets were mostly higher today. The STOXX Europe 600 Index rose 0.19%, London's FTSE 100 Index gained 0.23%, German DAX 30 Index dropped 0.14% and French CAC 40 Index rose 0.36%.
Asian markets ended mostly higher, with Japan's Nikkei Stock Average rising 0.91%, China's Shanghai Composite dropping 0.60% and Australia's S&P/ASX 200 Index gaining 0.34%. Hong Kong's Hang Seng Index gained 0.35% and India's Sensex dropped 0.48%.
Broker Recommendation Analysts at Stephens upgraded KAR Auction Services (NYSE: KAR) from “equal weight” to “overweight.” The target price for KAR Auction has been raised from $19 to $23.
KAR Auction shares gained 0.21% to $19.59 in after-hours trading.
- Pluristem Therapeutics (NASDAQ: PSTI) announced today it has initiated the final validation steps for its new "state-of-the-art" manufacturing facility prior to taking possession of the facility. To read the full news, click here.
- Hanwha SolarOne Co (NASDAQ: HSOL) today announced it has reached an agreement with the Bank of Beijing for access to up to RMB 3.0 Billion (approximately US$475 million) of credit over the next twelve-month period. To read the full news, click here.
- R. R. Donnelley (NASDAQ: RRD) today announced that Daniel L. Knotts is being named Chief Operating Officer, succeeding John R. Paloian who is retiring after over 25 years in the industry and having served for more than five years as the company's COO. To read the full news, click here.
- Synergy Pharmaceuticals (NASDAQ: SGYP) announced today that dosing has commenced in a Phase IIb clinical trial of plecanatide to treat patients with constipation-predominant irritable bowel syndrome (IBS-C). To read the full news, click here.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.